MX2021009384A - Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. - Google Patents

Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.

Info

Publication number
MX2021009384A
MX2021009384A MX2021009384A MX2021009384A MX2021009384A MX 2021009384 A MX2021009384 A MX 2021009384A MX 2021009384 A MX2021009384 A MX 2021009384A MX 2021009384 A MX2021009384 A MX 2021009384A MX 2021009384 A MX2021009384 A MX 2021009384A
Authority
MX
Mexico
Prior art keywords
methods
storage diseases
lysosomic
disorders associated
treatment against
Prior art date
Application number
MX2021009384A
Other languages
English (en)
Spanish (es)
Inventor
Nigel Patrick Somerville Crawford
Tanya Zaremba Fischer
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2021009384A publication Critical patent/MX2021009384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021009384A 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. MX2021009384A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962800996P 2019-02-04 2019-02-04
US201962851433P 2019-05-22 2019-05-22
US201962894167P 2019-08-30 2019-08-30
US201962937618P 2019-11-19 2019-11-19
US202062962647P 2020-01-17 2020-01-17
PCT/US2020/016440 WO2020163244A1 (en) 2019-02-04 2020-02-03 Methods for treating symptoms and disorders associated with lysosomal storage diseases

Publications (1)

Publication Number Publication Date
MX2021009384A true MX2021009384A (es) 2021-09-10

Family

ID=69743942

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021009384A MX2021009384A (es) 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
MX2021009383A MX2021009383A (es) 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009383A MX2021009383A (es) 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.

Country Status (13)

Country Link
US (2) US20220016092A1 (https=)
EP (2) EP3920913A1 (https=)
JP (3) JP2022520747A (https=)
KR (2) KR20210123353A (https=)
CN (2) CN113645969A (https=)
AU (2) AU2020217659B2 (https=)
BR (2) BR112021015172A2 (https=)
CA (1) CA3128039A1 (https=)
IL (3) IL285304B2 (https=)
MX (2) MX2021009384A (https=)
SG (2) SG11202107842QA (https=)
TW (3) TW202045168A (https=)
WO (2) WO2020163245A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
JP2023512366A (ja) 2020-02-03 2023-03-27 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
AU2021311131B2 (en) 2020-07-24 2026-02-19 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (https=) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
KR101987736B1 (ko) * 2011-03-18 2019-06-11 젠자임 코포레이션 글루코실세라마이드 합성효소 억제제
CA2840224C (en) * 2011-06-22 2019-08-13 The General Hospital Corporation Treatment of proteinopathies
JO3713B1 (ar) * 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
EP3079695B1 (en) 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法

Also Published As

Publication number Publication date
CN113645969A (zh) 2021-11-12
TW202045167A (zh) 2020-12-16
JP2022520747A (ja) 2022-04-01
KR20210123352A (ko) 2021-10-13
CA3128039A1 (en) 2020-08-13
BR112021015172A2 (pt) 2021-09-28
JP2025072556A (ja) 2025-05-09
WO2020163244A1 (en) 2020-08-13
BR112021015099A2 (pt) 2021-10-05
TW202508582A (zh) 2025-03-01
WO2020163245A1 (en) 2020-08-13
IL285304B2 (en) 2025-10-01
IL285304A (en) 2021-09-30
SG11202107842QA (en) 2021-08-30
SG11202107844UA (en) 2021-08-30
AU2020218496A1 (en) 2021-08-26
JP7511567B2 (ja) 2024-07-05
IL285187A (en) 2021-09-30
TWI865485B (zh) 2024-12-11
CN113710249A (zh) 2021-11-26
AU2020217659B2 (en) 2025-04-17
CA3128041A1 (en) 2020-08-13
KR20210123353A (ko) 2021-10-13
IL313808A (en) 2024-08-01
US20220023273A1 (en) 2022-01-27
EP3920914A1 (en) 2021-12-15
US20220016092A1 (en) 2022-01-20
MX2021009383A (es) 2021-09-10
TW202045168A (zh) 2020-12-16
JP2022519274A (ja) 2022-03-22
EP3920913A1 (en) 2021-12-15
IL285304B1 (en) 2025-06-01
AU2020217659A1 (en) 2021-08-26
AU2020218496B2 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
MX2021009384A (es) Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
JP2020033360A5 (https=)
MX2022005465A (es) Metodos de tratamiento con modulador de miosina.
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
EP4706638A3 (en) Methods of treating heart failure by administering omecamtiv mecarbil
MX2020013607A (es) Sistemas y métodos para acceder a senos.
MX2023002024A (es) Métodos de tratamiento con modulador de miosina.
MX2012002082A (es) Terapia de acetato de glatiramero de baja frecuencia.
MX2022001623A (es) Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EP3818991A3 (en) Compositions and methods for treating diseases
BR112022021963A2 (pt) Inibidores macrocíclicos de peptidilarginina desiminases
JOP20240235A1 (ar) مركبات أريل غير متجانسة لمعالجة الألم
CO2024012872A2 (es) Tratamiento de neurofibromas plexiformes (pn) asociados a neurofibromatosis tipo 1 (nf1) en pacientes pediátricos con mirdametinib
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
CL2022000781A1 (es) Tratamientos cognitivos medicinales
SG11201900810WA (en) Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
PY1944026A (es) Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
JP2016504361A5 (https=)
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
MX2024005374A (es) Metodos para tratar la enfermedad de celulas falciformes con voxelotor.